Genzyme Oncology Clinical Trials

Alemtuzumab

CAM111: Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies

CAM203: Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia

CAM307: Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) Vs Chlorambucil in Patients with Progressive B-Cell Lymphocytic Leukemia

CAM314: Fludara Plus Alemtuzumab (Campath, MabCampath) Vs Fludara Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients

CAMNHL232: Phase I/II Study of CAMPATH in Patients with Relapsing or Refractory Non-Hodgkin’s Lymphoma

CAMNHL233: Rituximab Plus CAMPATH in Patients with Relapsed/Refractory Low-Grade or Follicular, CD20-Positive, B-Cell NHL

CAMMS223: A Phase II Study Comparing Low- and High-Dose CAMPATH and High-Dose Rebif in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

CAMMS32400507: Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study Two (CARE-MS SM II)

CAMMS323: Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study One (CARE-MS SM I)

Clolar^® (Clofarabine)

CLO151: Clofarabine in Adult Patients With Advanced Solid Tumors

CLO152: Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors

CLO221: Phase II Study of Clofarabine in Adult Patients with Refractory or Relapsed Acute Myelogenous Leukemia

CLO222: Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients

CLO212: Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)

CLO34100405: A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML) (CLASSIC I)

CLO24300606: A study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)

CLOMDS02507: A Dose Confirmation Study of Oral Clofarabine for Previously Treated Adult Patients With Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS).

CLO21800205: A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.

GC1008

GC100800305: Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma

For more information about these trials, please contact MedInfo@genzyme.com or 617-252-7832.

Terms and Conditions of Use | Privacy Policy | © 2002-2008 Genzyme Corporation. All rights reserved.